(FPRX), (BMY) Discovery Collaboration Agreement Novel Immuno-Oncology Therapies

Five Prime Therapeutics, Inc. (Nasdaq:FPRX) and Bristol-Myers Squibb Company (NYSE:BMY) announced today that they have signed a collaboration agreement for the discovery, development and commercialization of immuno-oncology therapies directed toward targets identified in two undisclosed immune checkpoint pathways using Five Prime’s proprietary target discovery platform.

Bristol-Myers Squibb will leverage Five Prime’s platform to advance its existing immuno-oncology programs by identifying the most viable drug targets for continued research and development. Drug candidates developed against these new and existing targets may be studied either as single agents or in combination with existing or potential Bristol-Myers Squibb immuno-oncology therapies.

“Immuno-oncology has the potential to be transformational in the treatment of cancer, and Bristol-Myers Squibb has an extensive clinical pipeline and discovery programs dedicated to maximizing this field of research,” said Francis Cuss, MB BChir, FRCP, executive vice president and chief scientific officer, Bristol-Myers Squibb. “Five Prime’s innovative technology platforms complement our immuno-oncology pipeline and will help expand our understanding of promising new therapeutic options for patients.”

“We are thrilled to enter this important collaboration with Bristol-Myers Squibb, an undisputed leader in the exciting field of immuno-oncology,” said Lewis T. “Rusty” Williams, M.D., Ph.D., President and Chief Executive Officer of Five Prime. “This strategic alliance is evidence that our protein discovery platform is ideally suited to identify novel immune checkpoint targets for the development of next generation immuno-oncology therapeutics.”

Under the terms of the agreement, Bristol-Myers Squibb will obtain exclusive, worldwide rights to develop and commercialize products directed toward certain protein targets identified by Five Prime prior to and during the collaboration. Bristol-Myers Squibb will make an upfront payment of $20 million to Five Prime and provide up to $9.5 million in research funding over the course of the research term. Additionally, Bristol-Myers Squibb will make a payment of approximately $21 million to acquire 4.9% of Five Prime’s outstanding common stock purchased at approximately a 30% premium. Five Prime will be eligible to receive up to $300 million in future development, regulatory and sales based milestone payments per collaboration target and tiered mid-single-digit rising to low-double-digit royalty payments on net sales of each product commercialized by Bristol-Myers Squibb.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases. Five Prime has leveraged its comprehensive library of human extracellular proteins and its proprietary high-throughput screening technologies to produce new targets for protein therapeutics to be advanced by partners or in the company’s internal pipeline. Five Prime currently has 2 therapeutics in clinical testing and a third anticipated to enter the clinic by the end of 2014. FP-1039 (GSK3052230) is a fibroblast growth factor (FGF) ligand trap being developed in collaboration with GlaxoSmithKline to treat multiple solid tumors. A global, multi-arm Phase 1b study of FP-1039 in combination with standard chemotherapy in FGFR1 gene-amplified squamous non-small cell lung cancer (NSCLC) and mesothelioma is underway. A second drug candidate is FPA008, a monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF1R) activation and is being developed to treat rheumatoid arthritis, is in a Phase 1 trial currently enrolling. FPA144 is a monoclonal antibody that blocks signaling through fibroblast growth factor receptor 2b (FGFR2b) and is glyco-engineered for enhanced antibody-dependent cytotoxicity. FPA144 is expected to begin a Phase 1 study in gastric cancer by the end of 2014.

For more information please see: www.fiveprime.com

Bristol-Myers Squibb Forward-Looking Statement

This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that this collaboration will lead to the discovery of new drug candidates, that clinical trials from this collaboration will support regulatory filings, or that any new drug candidates will receive regulatory approvals or, if approved, that they will become commercially successful products. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb’s business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2013, in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Five Prime Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Five Prime’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding the (i) advancement of immuno-oncology programs; (ii) development and commercialization of products; and (iii) Five Prime’s receipt of milestone payments and royalty payments. Factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Five Prime’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” contained therein. Except as required by law, Five Prime assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

(CPAH) Announces Renewal of Normal Course Issuer Bid

Company believes its common shares do not adequately reflect their underlying value and may purchase its common shares in the market

CounterPath Corporation
David Karp
Chief Financial Officer
(604) 628-9364
dkarp@counterpath.com
www.counterpath.com

(HAST) Agreement and Plan of Merger with Affiliate of Joel Weinshanker

AMARILLO, Texas, March 17, 2014  — Hastings Entertainment, Inc. (NASDAQ: HAST), a leading multimedia entertainment retailer (“Hastings”), today reported that it has entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Draw Another Circle, LLC (“Parent”) and Hendrix Acquisition Corp. (“Merger Sub”), which are each wholly-owned, directly or indirectly, by Joel Weinshanker.  Mr. Weinshanker is the President and sole shareholder of National Entertainment Collectibles Association, Inc., which holds approximately 12% of Hastings’ outstanding shares (“NECA”).  Pursuant to the Merger Agreement, Merger Sub will be merged with and into Hastings, with Hastings surviving the merger as a wholly-owned subsidiary of Parent, and each share of Hastings common stock held by a shareholder of Hastings (other than Mr. Weinshanker and his affiliates) will, upon completion of the merger, be converted into the right to receive a cash payment of $3.00 per share.

The $3.00 per share price represents a premium of approximately 57.1% over Hastings’ closing share price on March 14, 2014 and a premium of approximately 61.3% over the average trading price of Hastings’ common shares for the last 30 trading days ending on March 12, 2014.  The transaction is valued at approximately $21.4 million.

Hastings’ Board of Directors, acting upon the unanimous recommendation of a special committee of the board directors consisting of independent directors (the “Special Committee”), has unanimously approved the Merger Agreement and the transactions contemplated by the Merger Agreement and has resolved to recommend that Hastings’ shareholders vote in favor of approving the Merger Agreement at a special meeting of the shareholders called specifically for such purpose.

“NECA is a significant supplier of movie, book and video game merchandise and collectibles to the Hastings superstores, and we’ve had a close and growing business relationship with Mr. Weinshanker over the last decade.  Mr. Weinshanker, through his affiliation with the estates of Marilyn Monroe, Elvis Presley and Muhammad Ali, and his company’s management of Graceland, is one of the leading drivers of the lifestyle industry, and we believe Hastings’ business will continue to benefit from our relationship with him and NECA,” said John H. Marmaduke, Hastings’ Chairman and CEO.

Under the terms of the Merger Agreement, the closing of the merger, which is expected to occur in the second quarter of calendar 2014, is subject to shareholders holding at least two-thirds of Hastings’ outstanding shares voting their shares in favor of approving the Merger Agreement and the fulfillment or waiver of other customary conditions, as more particularly set forth in the Merger Agreement.

In addition, Mr. Marmaduke and related beneficial owners who, together with Mr. Marmaduke, hold approximately 32% of Hastings’ common stock, and NECA have each entered into agreements with Parent in which they have agreed to, among other things, vote all shares over which they have exercisable voting power in favor of the merger.  As a result, holders of approximately 44% of the Hastings’ common stock have committed to vote for the merger.

SunTrust Robinson Humphrey and George K. Baum Capital Advisors, Inc. are serving as financial advisors to the Special Committee.  Kelly Hart & Hallman LLP is serving as legal advisor to Hastings, Haynes and Boone, LLP is serving as legal advisor to the Special Committee and Cooley LLP is serving as legal advisor to Parent and its affiliated entities.

IMPORTANT ADDITIONAL INFORMATION WILL BE FILED WITH THE SEC

Hastings plans to file with the SEC and mail to its shareholders a Proxy Statement in connection with the transaction. The Proxy Statement will contain important information about Parent, Merger Sub, Mr. Weinshanker, Hastings, the transaction and related matters. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT CAREFULLY WHEN IT IS AVAILABLE.

Investors and security holders will be able to obtain free copies of the Proxy Statement and other documents filed with the SEC by Hastings through the web site maintained by the SEC at www.sec.gov or by phone, email or written request by contacting Hastings at the following:

Address: 3601 Plains Boulevard, Amarillo, Texas 79102
Phone: (806) 677-1402
Email: dan.crow@goHastings.com

PARTICIPANTS IN THE SOLICITATION

Hastings and its directors, executive officers and certain other members of management and employees of Hastings may be deemed “participants” in the solicitation of proxies from shareholders of Hastings in favor of the proposed merger. Information regarding the persons who may, under the rules of the Securities and Exchange Commission, be considered participants in the solicitation of the shareholders of Hastings in connection with the proposed merger, and their direct or indirect interests, by security holdings or otherwise, which may be different from those of Hastings’ shareholders generally, will be set forth in the Proxy Statement and the other relevant documents to be filed with the Securities and Exchange Commission. You can find information about certain of Hastings’ executive officers and its directors in its Annual Report on Form 10-K for the fiscal year ended January 31, 2013.

Safe Harbor Statement

This press release contains “forward-looking statements,” including statements as to our belief that Hastings’ business will continue to benefit from its relationship with Mr. Weinshanker and NECA and our expectation that the acquisition will close in the second quarter of fiscal 2014.  These forward-looking statements are being made pursuant to the safe harbor provided by the Private Securities Litigation Reform Act of 1995, as amended, and are based on currently available information and represent the beliefs of the management of Hastings.  These statements are subject to risks and uncertainties that could cause actual results to differ materially.

These factors include, but are not limited to, (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement after it has been signed, (2) the outcome of any legal proceedings that may be instituted against Hastings or others following the announcement of the Merger Agreement, (3) the inability to complete the merger due to an insufficient number of votes by Hastings’ shareholders in favor of the Merger Agreement or the failure to satisfy other conditions contained in the Merger Agreement, (4) the risks that the proposed transaction disrupts current plans and operations of Hastings, (5) the actual timing of the closing of the acquisition, and (6) the costs, fees and expenses related to the transaction.  We undertake no obligation to affirm, publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.  Shareholders of Hastings are cautioned not to place undue reliance on the forward-looking statements included in the Press Release, which speak only as of the date such statements are made.  Please refer to Hastings’ annual, quarterly, and periodic reports on file with the Securities and Exchange Commission for a more detailed discussion of these and other risks that could cause results to differ materially.

About Hastings

Founded in 1968, Hastings’ is a leading multimedia entertainment retailer that combines the sale of new and used books, videos, video games and CDs, and trends and consumer electronics merchandise, with the rental of videos and video games in a superstore format.  We currently operate 126 superstores, averaging approximately 24,000 square feet, primarily in medium-sized markets throughout the United States.  We also operate three concept stores, Sun Adventure Sports, located in Amarillo, Texas and Lubbock, Texas, and TRADESMART, located in Littleton, Colorado.

We also operate www.goHastings.com, an e-commerce Internet web site that makes available to our customers new and used entertainment products and unique, contemporary gifts and toys.  The site features exceptional product and pricing offers.  The Investor Relations section of our web site contains press releases, a link to request financial and other literature and access to our filings with the Securities and Exchange Commission.

(VNRX) New Study Data, NuQ® Assays High Detection Rate of Prostate Cancer

Results Demonstrate Detection Rate of 80 Percent in Prostate Cancer

(GMCR) and Peet’s Coffee & Tea Announce Partnership

Keurig Green Mountain, Inc. (Keurig) (NASDAQ: GMCR), a leader in specialty coffee, coffee makers, teas and other beverages with its innovative brewing technology, and Peet’s Coffee & Tea, a premier specialty coffee and tea company, announced a multi-year manufacturing and distribution agreement for Peet’s-branded packs for the Keurig^® brewing system. Financial terms of the agreement were not disclosed.

The companies plan to launch a selection of Keurig® licensed Peet’s coffee and tea varieties in K-Cup^® packs for Keurig^® brewers produced by Keurig by the end of the summer. Peet’s will continue to hand roast the beans for its Peet’s K-Cup^® packs at its LEED-Gold certified roasting facility in Alameda, Calif. and the roasted beans will be transported to Keurig for grinding and packaging in K-Cup® packs.

The new, licensed Peet’s K-Cup^® packs will be distributed by Peet’s proprietary nationwide direct delivery system to grocery stores, mass merchandisers, club stores, Peet’s retail stores, and online at www.peets.com. Keurig will distribute Peet’s K-Cup® packs to specialty and department stores and away from home channels, as well as via its U.S. consumer direct site, www.keurig.com.

Peet’s entered the single-cup format just seven months ago and has quickly established a strong presence, expanding its distribution and retail sales of its single cup products, which are now available in over 12,000 stores nationwide.

“Consumers consistently choose the Keurig brewing system for the quality, simplicity, value and variety of the brands and beverages available in the system,” said Brian Kelley, Keurig’s President and CEO. “We’re thrilled to bring Keurig consumers and Peet’s lovers the choice of Peet’s premium specialty coffees and teas as part of the continually growing Keurig family of brands; hand roasted by Peet’s and expertly packaged in K-Cup packs by Keurig to deliver optimum freshness and taste with the ease of the Keurig brewing system.”

“We continue to have incredible growth and success in the single cup category as existing and new consumers have responded very favorably to the quality and experience of Peet’s in the single cup form over the past year,” said Dave Burwick, president and CEO of Peet’s Coffee & Tea. “We believe now is the right time to partner with Keurig and work together to further advance this important, growing category.”

Since Peet’s opened its first store in Berkeley, CA in 1966, the company has been steadfastly dedicated to crafting the highest quality coffee, as set forth by founder, Alfred Peet. Peet’s coffee buyers travel the world to select the finest coffee beans. Each batch of coffee is then hand-roasted before being immediately packaged and shipped to uphold a strict standard of freshness.

Keurig^® hot system brewers use innovative brewing technology to deliver a fresh-brewed, perfect single cup of hot or brewed over ice coffee, tea, cocoa, or fruit brews every time at just the touch of a button. With the launch of the next generation Keurig® 2.0 brewer expected this fall, Keurig consumers will be able to brew both a single cup and a carafe of coffee from a Keurig® brand pack. Consumers also will get the same Keurig quality, simplicity and beverage choice they expect with more than 50 brands and more than 290 beverage varieties currently available, all brewed with Keurig’s new beverage-optimizing brewing technology.

The Keurig® single cup brewing system was recently recognized as the “Brand of the Year” in the single serve coffee maker category in the 2014 Harris Poll EquiTrend® Equity Study. For the third consecutive year, the Keurig® system has received the highest ranking in the coffee maker category based on consumers’ perceptions of familiarity, quality and purchase consideration, a selection of several qualifying elements evaluated.

About Peet’s

Peet’s Coffee & Tea, Inc. is the premier specialty coffee and tea company in the United States. The company was founded in 1966 in Berkeley, Calif. by Alfred Peet. Peet was an early tea authority who later became widely recognized as the grandfather of specialty coffee in the U.S. Today, Peet’s Coffee & Tea offers superior quality coffees and teas in multiple forms, by sourcing the best quality coffee beans and tea leaves in the world, adhering to strict high-quality and taste standards, and controlling product quality through its unique direct store delivery selling and merchandising system. Peet’s is committed to strategically growing its business through many channels while maintaining the extraordinary quality of its coffees and teas.

For more information about Peet’s Coffee & Tea, Inc., visit www.peets.com.

About Keurig Green Mountain, Inc.

As a leader in specialty coffee, coffee makers, teas and other beverages, Keurig Green Mountain (Keurig) (NASDAQ: GMCR), is recognized for its award-winning beverages, innovative Keurig^® brewing technology, and socially responsible business practices. The Company has inspired consumer passion for its products by revolutionizing beverage preparation at home and in the workplace. Keurig supports local and global communities by investing in sustainably-grown coffee and by its active involvement in a variety of social and environmental projects. By helping consumers drink for themselves, we believe we can brew a better world. For more information visit: www.KeurigGreenMountain.com. To purchase Keurig^® products visit: www.Keurig.com or www.Keurig.ca.

Keurig routinely posts information that may be of importance to investors in the Investor Relations section of its website, www.KeurigGreenMountain.com, including news releases and its complete financial statements, as filed with the SEC. The Company encourages investors to consult this section of its website regularly for important information and news. Additionally, by subscribing to the Company’s automatic email news release delivery, individuals can receive news directly from Keurig as it is released.

Keurig Green Mountain Forward-Looking Statements

Certain information in this filing constitutes “forward-looking statements.” Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. They often include words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “seeks” or words of similar meaning, or future or conditional verbs, such as “will,” “should,” “could,” “may,” “aims,” “intends,” or “projects.” However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. These statements may relate to: the expected impact of raw material costs and our pricing actions on our results of operations and gross margins, expected trends in net sales and earnings performance and other financial measures, the expected productivity and working capital improvements, the success of introducing and producing new product offerings, the impact of foreign exchange fluctuations, the adequacy of internally generated funds and existing sources of liquidity, such as the availability of bank financing, the expected results of operations of businesses acquired by us, our ability to issue debt or additional equity securities, our expectations regarding purchasing shares of our common stock under the existing authorizations, projections of payment of dividends, and the impact of the inquiry initiated by the SEC and any related litigation or additional governmental inquiry or enforcement proceedings. A forward-looking statement is neither a prediction nor a guarantee of future events or circumstances, and those future events or circumstances may not occur. Management believes that these forward-looking statements are reasonable as and when made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We expressly disclaim any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our Company’s historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in Part I, “Item 1A. Risk Factors,” and Part II “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our fiscal 2013 Annual Report filed on Form 10-K with the Securities and Exchange Commission.

Actual results could differ materially from those projected in the forward-looking statements. We expressly disclaim any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

(DRAD) Acquires Telerhythmics

Outsourced Cardiac Monitoring Service for Physicians and Hospitals

SUWANEE, Ga., March 14, 2014  — Digirad Corporation (Nasdaq:DRAD), the leader in providing diagnostic imaging services and technology on an as needed, where needed, and when needed basis, announced today that it has acquired all the outstanding membership interest of Telerhythmics, LLC, a 24-hour cardiac event monitoring service used on an outsourced basis by hospitals and physician offices. Based in Memphis, Tennessee, privately-held Telerhythmics provides its monitoring services throughout the eastern region of the U.S.

Total up front consideration for the purchase was approximately $3.6 million, which included a $3.47 million cash payment up front and assumption of approximately $131,000 in debt. In addition, there is an earn-out opportunity of up to $501,000 over approximately three years based on meeting certain EBITDA targets. Telerhythmics will continue to operate from its current facility in Memphis. Further information is contained in a Form 8-K filed today with the U.S. Securities and Exchange Commission.

Digirad President and CEO Matthew G. Molchan commented, “Telerhythmics, like Digirad’s DIS operations, is a platform business that can support additional services, and cardiac event monitoring is an important outsourced service. Telerhythmics is also a solid, entrenched enterprise with nearly 20 years in the business and has a high quality reputation in the industry.”

Telerhythmics generated approximately $5.6 million in revenue in 2013. Once Telerhythmics goes through a short integration period, it is expected to be accretive on an EBITDA basis. Under Digirad’s ownership and at the 2013 level of annual revenue, it is expected the business will generate approximately $350,000 of EBITDA in the first twelve months, and then approximately $800,000 of EBITDA annually thereafter.

Molchan continued, “The addition of Telerhythmics fits squarely in our business model and our mission to provide medical services and technology on an as needed, where needed and when needed basis. Its target market is virtually the same as our target market with DIS, and acquiring Telerhythmics allows us to drive additional services via our existing channels and expand and diversify our business operations, allowing us more opportunities to grow and broaden our geographic reach.”

About Digirad Corporation

Digirad is one of the largest national providers of in-office nuclear cardiology imaging, ultrasound imaging services and cardiac event monitoring services to physician practices, hospitals and imaging centers. Digirad also sells medical diagnostic imaging systems for nuclear cardiology and general nuclear medicine applications. For more information, please visit www.digirad.com. Digirad^® and Cardius^® are registered trademarks of Digirad Corporation.

Forward-Looking Statements

This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. Some of these forward-looking statements can be identified by the use of forward-looking words such as “believes,” “expects,” “may,” “will,” “should,” “seek,” “approximately,” “intends,” “plans,” “estimates,” or “anticipates,” or the negative of those words or other comparable terminology, or in specific statements such as the Company’s ability to deliver value to customers, the ability to grow and generate positive cash flow, the ability to execute on restructuring activities, and ability to successfully execute acquisitions. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the statements made, including the risks associated with changes in business conditions, technology, customers’ business conditions, reimbursement, radiopharmaceutical shortages, economic outlook, operational policy or structure, acceptance and use of Digirad’s camera systems and services, reliability, recalls, analysis of potential impairment and restructuring charges, the conclusion of our audit and other risks detailed in Digirad’s filings with the U.S. Securities and Exchange Commission, including the Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other reports. Readers are cautioned to not place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Digirad undertakes no obligation to revise or update the forward-looking statements contained herein.

CONTACT: For more information contact:
         Jeffry Keyes
         Chief Financial Officer
         858-726-1600
         ir@digirad.com

(LTBR) to Host March 28 Conference Call, Webcast on 2013 Business Update, Financials

Live Conference Call and Webcast Scheduled at 11 a.m. ET Friday, March 28, at:
http://www.media-server.com/m/p/occurz2m

MCLEAN, Va., March 14, 2014  — Lightbridge Corporation (Nasdaq:LTBR), a leading innovator of next generation nuclear fuel designs and provider of nuclear energy consulting services to commercial and governmental organizations, today announced that the conference call and webcast to discuss its business update and 2013 financial results is scheduled for 11 a.m. ET Friday, March 28, 2014. President and Chief Executive Officer Seth Grae will lead the call. Other Lightbridge executives also will be available to answer questions. The business update news release with financial results is planned for distribution after the market close on Thursday, March 27.

Questions may be asked live, using the telephone lines below. Questions also may be submitted in writing before or during the conference call to ir@ltbridge.com. All written questions will be read and answered during the call.

About Lightbridge Corporation

Lightbridge is a U.S. nuclear energy company based in McLean, Virginia with operations in Abu Dhabi, Moscow and London. The Company develops proprietary, proliferation resistant, next generation nuclear fuel technologies for current and future nuclear reactor systems. The Company also provides comprehensive advisory services for established and emerging nuclear programs based on a philosophy of transparency, non-proliferation, safety and operational excellence.  Lightbridge’s breakthrough fuel technology is establishing new global standards for safe and clean nuclear power and leading the way to a sustainable energy future. Lightbridge consultants provide integrated strategic advice and expertise across a range of disciplines including regulatory affairs, nuclear reactor procurement and deployment, reactor and fuel technology and international relations.  The Company leverages those broad and integrated capabilities by offering its services to commercial entities and governments with a need to establish or expand nuclear industry capabilities and infrastructure.

Lightbridge is on Twitter. Sign up to follow @LightbridgeCorp at http://twitter.com/lightbridgecorp.

Forward Looking Statements

This news release contains statements that are forward-looking in nature within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s competitive position and product and service offerings.  These statements are based on current expectations on the date of this press release and involve a number of risks and uncertainties, which may cause actual results to differ significantly from such estimates.  The risks include, but are not limited to, the degree of market adoption of the Company’s product and service offerings; market competition; dependence on strategic partners; and the Company’s ability to manage its business effectively in a rapidly evolving market.  Certain of these and other risks are set forth in more detail in Lightbridge’s filings with the Securities and Exchange Commission.  Lightbridge does not assume any obligation to update or revise any such forward-looking statements, whether as the result of new developments or otherwise.

CONTACT: Gary Sharpe
         Investor Relations and Corporate Communications
         Lightbridge Corporation
         571-730-1213, direct
         gsharpe@ltbridge.com

(HART) Regenerative Technology Posts Updated Investor Presentation on Its Website

Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, has posted an updated version of its investor presentation on its website.

To view the updated investor presentation, please visit the following link:

http://www.harvardapparatusregen.com/media/wysiwyg/HART/PDFs/IR_Presentation.pdf

About Harvard Apparatus Regenerative Technology

Harvard Apparatus Regenerative Technology makes regenerated organs for transplant. Our first product, the InBreath^TM Airway Transplant System, is intended to replace or repair a trachea that has been severely damaged by either trachea cancer or physical trauma. Our technology has been used in eight human trachea transplants to date approved under compassionate use exemptions, but none of our products are yet approved by a government regulatory authority for marketing. On November 1, 2013, HART was spun-off from Harvard Bioscience. The trademark “Harvard Apparatus” is used under a sublicense agreement with Harvard Bioscience, who has licensed the right to use such trademark from Harvard University.

(NEWL) to Acquire Two Eco-Type 2012-Built Handysize Vessels

PIRAEUS, Greece, March 14, 2014  — NewLead Holdings Ltd. (NASDAQ: NEWL) (“NewLead” or the “Company”) today announced that it has executed definitive agreements for the acquisition of two eco-type 31,800 dwt, Handysize bulk carriers built in 2012 for a total acquisition price of $37.0 million.

The two eco-type vessels are expected to be delivered in NewLead by the end of June and July this year. Upon completion of this acquisition, NewLead will own five dry-bulk vessels, consisting of three Handysize and two Panamax vessels.

The Company expects to finance the acquisition of the two vessels through the combination of proceeds from its recent preferred shares issuance along with the 75% debt financing, as previously announced. On March 11, 2014, NewLead paid a deposit of $1.85 million to the acquisition price, and the remaining $7.4 million, not subject to the debt financing, is expected to be paid in installments upon delivery of the two vessels.

Michael Zolotas, President and Chief Executive Officer of NewLead, stated, “We are pleased to bring into NewLead two more eco-type dry bulk Handysize vessels at a competitive price with a upside in market value, a 23 year employment lifetime, unlimited trading flexibility and projected EBITDA and OPEX of $4.0 million and $1.73 million, respectively, per year per vessel as per current market levels.”

About NewLead Holdings Ltd.

NewLead Holdings Ltd. is an international, vertically integrated shipping and commodity company that manages product tankers and dry bulk vessels. NewLead currently owns two dry bulk vessels and has agreements to acquire three eco-type Handysize dry bulk vessels, one of which is a newbuilding. NewLead owns a wash plant and a mine in Kentucky, USA. NewLead’s common shares are traded under the symbol “NEWL” on the NASDAQ Global Select Market. To learn more about NewLead Holdings Ltd., please visit the new website at www.newleadholdings.com.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995

This press release includes assumptions, expectations, projections, intentions and beliefs about future events. These statements, as well as words such as “anticipate,” “estimate,” “project,” “plan,” and “expect,” are intended to be ”forward-looking” statements. We caution that assumptions, expectations, projections, intentions and beliefs about future events may vary from actual results and the differences can be material. Forward-looking statements include, but are not limited to, such matters as the creditworthiness of our counterparties, the reliability of reserve reports, our ability to extract or acquire coal to fulfill contracts, the consummation of conditional contracts, future operating or financial results; our liquidity position and cash flows, our ability to borrow additional amounts under our revolving credit facility and, if needed, to obtain waivers from our lenders and restructure our debt, and our ability to continue as a going concern; statements about planned, pending or recent vessel disposals and/or acquisitions, business strategy, future dividend payments and expected capital spending or operating expenses, including dry-docking and insurance costs; statements about trends in the product tanker and dry bulk vessel shipping segments, including charter rates and factors affecting supply and demand; expectations regarding the availability of vessel acquisitions; completion of repairs; length of off-hire; availability of charters; and anticipated developments with respect to any pending litigation. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, management’s examination of historical operating trends, data contained in our records and other data available from third parties. Although NewLead believes that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, NewLead cannot assure you that it will achieve or accomplish these expectations, beliefs or projections described in the forward looking statements. Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include the strength of world economies and currencies, general market conditions, including changes in charter rates and vessel values, failure of a seller to deliver one or more vessels, and other factors discussed in NewLead’s filings with the U.S. Securities and Exchange Commission from time to time. NewLead expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in NewLead’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Investor and Media Relations:
Elisa Gerouki
NewLead Holdings Ltd.
Telephone: + 30 213 014 8023
Email: egerouki@newleadholdings.com

(MNGA) to Exhibit and CEO to Moderate Panel at Largest Bio Mass Conference in North America

Company expected to unveil liquid biomass solution

TAMPA, Fla., March 14, 2014  — MagneGas Corporation, www.magnegas.com (“MagneGas” or the “Company”) (NASDAQ: MNGA), a leading technology company that counts among its inventions a technology that converts liquid waste into a hydrogen-based fuel, will be exhibiting and its CEO will be moderating a panel called “Making it Work: How Digester Designs Evolve to Meet Unique Operating Conditions,” at the 7^th Annual International Biomass Conference & Expo. The Biomass Conference & Expo is the largest of its kind in North America and upwards of 1500 attendees are expected to be on hand for the 3 day conference being held from March 24^th to the 26^th at the Orange County Convention Center in Orlando, FL.

In addition to exhibiting and participating in one of several breakout sessions to be held at the conference, MagneGas has planned a major industry announcement to unveil its liquid biomass technology solution. The company will be using the targeted audience and heightened interest in biomass and related industries to bring attention to a technology that will, “Reset the way we view and deal with liquid waste,” says MagneGas CEO Ermanno Santilli. “Whether you are in the livestock, feed, waste energy/water and a number of other sectors, this technology will have a profound impact and we are excited to be able to premier it at this conference.”

MagneGas will be exhibiting its liquid biomass technology solution at booth #511 at the convention center and company officials will be on hand to talk and answer questions. Media interested in speaking with MagneGas officials either on site or by phone can contact Shelby Malvestuto at 727-934-3448 and shelbymalvestuto@magnegas.com.

About MagneGas Corporation

Founded in 2007, Tampa-based MagneGas Corporation (NASDAQ: MNGA) is the producer of MagneGas, a natural gas alternative and metal working fuel that can be made from certain industrial, municipal, agricultural and military liquid wastes following the receipt of appropriate governmental permits.

The Company’s patented Plasma Arc Flow process gasifies liquid waste, creating a clean burning hydrogen based fuel that is essentially interchangeable with natural gas. MagneGas can be used for metal working, cooking, heating, powering bi-fuel automobiles and more. For more information on MagneGas, please visit the Company’s website at www.MagneGas.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  These statements relate to future events, including our ability to raise capital, or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The Company is currently using new ethylene glycol to produce fuel until proper permits to process used liquid waste have been obtained.

For a discussion of these risks and uncertainties, please see our filings with the Securities and Exchange Commission. Our public filings with the SEC are available from commercial document retrieval services and at the website maintained by the SEC at http://www.sec.gov.

(UNIS) Secures $60 Million Debt Financing with OrbiMed Advisors

YORK, Pa., March 13, 2014  — Unilife Corporation (“Unilife” or “Company”) (NASDAQ: UNIS, ASX: UNS) today announced that it has entered into a $60 million debt financing agreement with an affiliate of OrbiMed (“OrbiMed”).

$40 million was funded to Unilife at the closing of the deal. Provided the Company is in compliance with the terms of the agreement, two additional tranches of $10 million each will be provided to Unilife in December 2014 and June 2015.

During the six year term of the agreement, Unilife will make interest-only payments to OrbiMed currently calculated at a rate of 10.25% per annum, with the principal to be repaid by March 12, 2020 (“Maturity Date”).  OrbiMed will also receive a tiered royalty payment based on net sales generated by Unilife during each fiscal year of the agreement. The maximum royalty rate is 2.75% of annual net sales. The royalty rate decreases as annual net sales increases. Total royalties paid to OrbiMed under the agreement are capped as Unilife has the option to buy out the royalty payment, which is at a reduced amount at any time on or before the fourth anniversary of the agreement. No equity or warrants were or will be issued as part of this agreement.

Mr. Alan Shortall, Chairman and CEO of Unilife, said: “OrbiMed is one of the premier healthcare investors in the world. With OrbiMed and their independent advisors having conducted extensive due diligence into all aspects of our business, including our products, IP and commercial pipeline, we believe this agreement represents a significant endorsement of Unilife. In particular, I believe OrbiMed’s decision to accept a small share of our future net sales highlights their confidence in our business model and future growth.

“This $60 million commitment provides us with the necessary capital to drive business growth as we bring several large contracts with existing customers through to commercial rollout. Our decision to take only $40 million of the $60 million upfront will ensure we have the cash to support our operations while minimizing interest payments. I believe Unilife’s growing base of customers will view our long-term partnership with OrbiMed as a positive development, as it further strengthens our business position and capacity to meet their future needs,” Mr. Shortall concluded.

About Unilife Corporation
Unilife Corporation (NASDAQ:UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife’s broad portfolio of proprietary technologies includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, ocular delivery systems and novel systems. Each of these innovative and highly differentiated platforms can be customized to address specific customer, drug and patient requirements. Unilife’s global headquarters and state-of-the-art manufacturing facilities are located in York, PA. For more information, please visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or Android device.

About OrbiMed
OrbiMed (www.orbimed.com) is a leading investment firm dedicated exclusively to the healthcare sector, with approximately $10 billion in assets under management. OrbiMed invests globally across the spectrum of healthcare companies, from venture capital start-ups to large multinational companies. OrbiMed’s team of more than 80 employees manages a series of private equity funds, public equity funds, royalty/debt funds and other investment vehicles. OrbiMed maintains its headquarters in New York City, with additional offices in San Francisco, Shanghai, Mumbai and Herzliya.

Forward-Looking Statements
This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management’s beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in “Item 1A. Risk Factors” and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.

General: UNIS-G

(PLM) EIS Receives Significantly Improved EPA Rating

Media: PolyMet Mining Corp.
Bruce Richardson
Corporate Communications
+1 (651) 389-4111
brichardson@polymetmining.com

Investor Relations: PolyMet Mining Corp.
Jenny Knudson
Investor Relations
+1 (651) 389-4110
jknudson@polymetmining.com
www.polymetmining.com

(GSOL) intended cash tender offer

NEW YORK, March 13, 2014  — Global Sources Ltd. (NASDAQ: GSOL) intends to commence an issuer tender offer before the end of April 2014, with expected completion before the end of May 2014, for approximately 5 million shares, or approximately 14.4% of its outstanding common shares as of Feb. 28, 2014, at a purchase price of $10.00 per share in cash.  Global Sources expects to fund the tender offer with cash on hand.  As of Dec. 31, 2013, Global Sources had total cash, cash equivalents and available-for-sale securities of approximately $143.8 million.

The offer will afford tendering shareholders liquidity for some or all of their shares and will permit them to have their shares repurchased at a 47.9% premium over the closing price per share of $6.76 on March 12, 2014, the last full trading day before the date of this announcement. Shareholders who elect not to tender their shares in the offer will increase their relative percentage ownership in Global Sources following completion of the offer.

Global Sources’ executive chairman, Merle A. Hinrich, said: “I am pleased to announce that the Board of Directors has approved a tender offer.  We believe this measure enables all shareholders to participate equally in a return of investment, if so chosen.”

Global Sources has been informed that its Directors and Officers who own shares can be expected to tender their shares in the offer. Such Directors and Officers beneficially owned approximately 48.6% of Global Sources’ outstanding common shares as of Feb. 28, 2014.

THIS PRESS RELEASE CONSTITUTES NEITHER AN OFFER TO BUY NOR THE SOLICITATION OF AN OFFER TO SELL SHARES. THE SOLICITATION AND THE OFFER TO BUY GLOBAL SOURCES’ COMMON SHARES WILL ONLY BE MADE PURSUANT TO AN OFFER TO PURCHASE AND RELATED MATERIALS THAT GLOBAL SOURCES EXPECTS TO BEGIN DISTRIBUTING TO ITS SHAREHOLDERS BEFORE THE END OF APRIL 2014. SHAREHOLDERS SHOULD READ THESE MATERIALS CAREFULLY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING VARIOUS TERMS AND CONDITIONS OF THE OFFER. SHAREHOLDERS WILL BE ABLE TO OBTAIN FOR FREE THE OFFER TO PURCHASE AND OTHER FILED DOCUMENTS AT THE SEC’S WEBSITE AT HTTP://WWW.SEC.GOV. ONCE AVAILABLE, THESE DOCUMENTS MAY ALSO BE OBTAINED FOR FREE IN THE INVESTOR RELATIONS SECTION OF GLOBAL SOURCES’ WEBSITE AT GLOBALSOURCES.COM.

About Global Sources

Global Sources is a leading business-to-business media company and a primary facilitator of trade with Greater China.

The core business facilitates trade between Asia and the world using English-language media such as online marketplaces (GlobalSources.com), print and digital magazines, sourcing research reports, private sourcing events, and trade shows.

More than 1 million international buyers, including 95 of the world’s top 100 retailers, use these services to obtain product and company information to help them source more profitably from overseas supply markets. These services also provide suppliers with integrated marketing solutions to build corporate image, generate sales leads and win orders from buyers in more than 240 countries and territories.

Global Sources’ other businesses provide Chinese-language media to companies selling to and within Greater China. These services include online web sites, print and digital magazines, seminars and trade shows. In mainland China, Global Sources has a network of more than 30 office locations and a community of more than 4 million registered online users and magazine readers of its Chinese-language media.

Now in its fifth decade, Global Sources has been publicly listed on the NASDAQ since 2000.

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of Section 27-A of the Securities Act of 1933, as amended and Section 21-E of the Securities Exchange Act of 1934, as amended. The company’s actual results could differ materially from those set forth in the forward-looking statements as a result of the risks associated with the company’s business, changes in general economic conditions, and changes in the assumptions used in making such forward-looking statements.

(APPY) Announces Positive Top-Line Results from Pivotal Study of APPY1 Test

Achieved Negative Predictive Value and Sensitivity ~97% and Specificity ~38% Conference Call and Webcast Today, March 13, 2014, 8:30am ET

CASTLE ROCK, Colo., March 13, 2014  — Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1™ Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced positive top-line results from its pivotal U.S. study.  The APPY1 Test performed well, with sensitivity and negative predictive value results that exceeded those from the previous pilot study.  The company believes these pivotal results are sufficient for potential FDA clearance and expects to finalize its 510(k) submission and file with the FDA in the next few weeks.

In the measure of negative predictive value (NPV), which is the primary metric for the APPY1 Test, the results were 97.3%, with a lower 95% confidence limit of 95.5%.  Additionally, the APPY1 Test performed with sensitivity of 96.9% (lower 95% confidence limit of 94.9%).  Specificity for APPY1 was 37.8% (lower 95% confidence limit of 35.3%), which is believed to be adequate for an adjunctive, negative predictive test such as the APPY1 Test.  Overall prevalence of appendicitis was 25%, which was also in line with expectations and the medical literature.

Top line data statistics for the recently completed pivotal clinical study (CP-12) as compared to the prior pilot study (CP-11), are summarized as follows:

Principal study investigator Dave Huckins, M.D., stated, “These top-line results reflect improved test performance for negative predictive value and sensitivity compared to Venaxis’ previous 500-patient pilot study.  This is highly significant for a number of reasons.  In addition to involving many more hospital sites and patients, for the first time in this pivotal study the APPY1 Test was performed on-site in real time at each participating hospital, by hospital personnel, as the test would be run in the real clinical setting. The pivotal study also enrolled a more ethnically diverse patient demographic compared with the previous 500-patient pilot study.  The fact that the APPY1 Test performance matched, and even improved upon, the previous results in the face of these ‘real world’ factors adds significant robustness to the pivotal study results.”

Steve Lundy, President and CEO of Venaxis™, stated, “The positive outcome from this study is a significant achievement for Venaxis, and I want to commend our team and our clinical partners on a very well-run study. Also of note, the APPY1 Tests used during the study were produced from multiple manufacturing lots, demonstrating their reproducibility. We are working now to complete our analysis of the data for inclusion into our 510(k) package to the FDA, which we expect to submit in the next few weeks.  While we await its review, our market development activities continue to accelerate not only in Europe, but also in in the United States, where we’ve begun collecting important hospital and physician market data and identifying hospitals that have significant influence and community outreach.  Our goal is to be well positioned for successful product launch upon potential FDA clearance of the APPY1 Test.”

Conference Call Information:

Interested participants and investors may access the conference call by dialing 1-877-870-4263 (U.S.), 1-855-669-9657 (Canada) or 1-412-317-0790 (international).  A live audio webcast will be accessible via the Investor Relations section of the Venaxis web siteir.venaxis.com.

A telephonic replay of the call will be available for 90 days beginning approximately on hour after the end of the conference call through June 13, 2014.  Access numbers for this replay are 1-877-344-7529 (U.S./Canada) and 1-412-317-0088 (international); conference ID: 10042671.  The webcast replay will remain available in the Investors Relations section of the Venaxis web site for 90 days.

About Venaxis, Inc.

Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its CE Marked APPY1 Test, the Company’s rapid, protein biomarker-based assay for appendicitis.  This unique appendicitis test has projected high sensitivity and negative predictive value and is being developed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management.  The APPY1 Test is being developed initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging.  While FDA clearance is being sought, a commercial launch for the APPY1 Test is ongoing in select European countries.  For more information, visit www.venaxis.com.

Forward-Looking Statements

This press release includes “forward-looking statements” of Venaxis, Inc. (“Venaxis”) as defined by the Securities and Exchange Commission (“SEC”). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial data analysis and related activities for the APPY1 Test required for FDA submission, obtain FDA clearance or approval, maintain CE Marking, cost effectively manufacture and generate revenues from the APPY1 Test at a profitable price point, execute agreements required to successfully advance the company’s objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, Venaxis does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in Venaxis’ recent filings with the SEC, including its Form 10-Q for the quarter ended June 30, 2013.

Venaxis and APPY1 are trademarks of Venaxis, Inc.

For Investors and Media:
Tiberend Strategic Advisors, Inc.
Joshua Drumm, PhD, jdrumm@tiberend.com; (212) 375-2664
Claire Sojda, csojda@tiberend.com; (212) 375-2686

(LPHI) Cleared of All Fraud Claims

Life Partners Holdings, Inc. (Nasdaq GS: LPHI) announced today that an Austin Federal court has ruled that the Securities and Exchange Commission failed to prove any of its fraud claims against Life Partners and its CEO, Brian Pardo, and General Counsel, Scott Peden. The ruling followed a jury finding in February that neither Life Partners, Mr. Pardo nor Mr. Peden committed securities fraud under Rule 10b-5 and that Mr. Pardo and Mr. Peden did not engage in insider trading.

In the earlier ruling, the jury had found in favor of the SEC’s fraud claim under Section 17(a) relating to the company’s revenue recognition policies. That claim, which a government attorney characterized as “a lead” claim in the case, was challenged by Life Partners on the basis that it was not supported by any evidence. The United States District Court for the Western District of Texas, Austin Division agreed with Life Partners that there was no evidence to support the revenue recognition claims for the period of time in question and ordered that judgment be entered in favor of Life Partners, Mr. Pardo and Mr. Peden on that issue. As a result of this ruling, the Company, Mr. Pardo and Mr. Peden have been completely exonerated from any allegations of fraud alleged by the SEC.

The Court let stand the jury’s findings against Life Partners relating to bookkeeping, reporting and certification by the CEO on the company’s financial statements, none of which involve fraud or knowingly or recklessly misleading shareholders.

Life Partners’ CEO, Brian Pardo, said, “We are very pleased with both the jury verdict and this ruling. This experience should remind all of us that it takes more than accusations, claims and innuendo to win in court. It takes evidence. Now that we have moved past these accusations of fraud, we can move forward as a company bringing value to both senior Americans and our shareholders. Life settlements, as transacted through Life Partners, provide a valuable service to senior Americans who want to sell their unwanted life insurance policies and are a tremendous alternative asset class for accredited investors seeking to avoid the volatility of the stock market and enjoy the potential for superior returns on investment.”

The case is SEC v. Life Partners Holdings, Inc. et al., Civil Action No. 1-12-C V-33-JRN in the United States District Court for the Western District of Texas, Austin Division.

Life Partners is the world’s oldest and one of the most active companies in the United States engaged in the secondary market for life insurance, commonly called “life settlements”. Since its incorporation in 1991, Life Partners has completed over 155,000 transactions for its worldwide client base of over 30,000 high net worth individuals and institutions in connection with the purchase of over 6,500 policies totaling over $3.2 billion in face value.

(TSRO) AnaptysBio And TESARO Announce Strategic Immuno-Oncology Antibody Collaboration

SAN DIEGO, March 13, 2014  — AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced a strategic immuno-oncology collaboration with TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company.   Under the terms of the agreement, AnaptysBio has granted TESARO exclusive rights to antibody programs targeting PD-1, TIM-3 and LAG-3, including monospecific and dual reactive antibody drug candidates.  Antibody candidates from these programs are expected to enter clinical trials over the next 18 to 24 months.

Under the terms of this agreement, TESARO will pay an upfront license fee of $17 million, as well as provide funding of costs incurred by AnaptysBio related to the development programs. For each development program, AnaptysBio is eligible to receive milestone payments of $18 million if certain research and development events are achieved and an additional $90 million associated with certain U.S. and ex-U.S. regulatory submissions and approvals in multiple indications.   AnaptysBio will also be eligible to receive tiered single-digit royalties related to worldwide net sales of products developed under the collaboration and certain commercial milestone payments if specified levels of annual worldwide net sales are attained.  AnaptysBio and TESARO will together complete preclinical development of the antibody candidates, with TESARO being solely responsible for all clinical development, manufacturing, regulatory and commercial activities.

Each of the antibodies licensed under this collaboration has been developed using AnaptysBio’s proprietary SHM-XEL platform.  By replicating the natural process of somatic hypermutation in vitro, the platform permits rapid generation of high potency therapeutic antibodies selected for desired functional activity and robust biophysical properties.  The SHM-XEL platform has been successful in generating therapeutic antibodies for AnaptysBio’s internal pipeline and under various pharmaceutical company  partnerships.

“AnaptysBio’s SHM-XEL platform has generated highly potent therapeutic antibodies against multiple immuno-oncology checkpoint receptors.  In addition to selecting for antibodies with optimal checkpoint antagonist function, our mammalian cell display system permits simultaneous selection for high antibody expression, stability and robust biophysical features required for successful development and ideal pharmacokinetic properties,” said Hamza Suria, president and CEO of AnaptysBio. “Our programs attracted partnership proposals from several companies interested in developing novel immuno-oncology antibody combinations.  We specifically chose to collaborate with TESARO because of its strategic focus in oncology and the proven expertise of TESARO’s development team. We look forward to working with TESARO to advance these therapies to the clinic and deliver new treatment options for cancer patients.”

Antibodies to immune checkpoint receptors have recently demonstrated promise in the treatment of various solid tumors, including metastatic melanoma, renal cell carcinoma and non-small cell lung cancer.  Although the normal function of immune checkpoint receptors is to maintain immune homeostasis, they are co-opted by certain tumors to evade immune surveillance.  By blocking the interaction of PD-1, TIM-3 and LAG-3 with their respective ligands, the antibodies exclusively licensed under this collaboration aim to restore immune function in cancer patients across a variety of tumor types.

“In our view, immunotherapy-based approaches are likely to transform the way that cancer is treated and may become the foundation of many future cancer therapy regimens,” said Mary Lynne Hedley, president of TESARO. “The AnaptysBio platform offers unmatched capabilities in antibody discovery, generation and optimization, and we are excited about the potential for these programs. We look forward to working with the AnaptysBio team to develop novel immuno-oncology-based approaches to a variety of tumors.”

About AnaptysBio

AnaptysBio is a privately-held company focused on the generation of antibody therapeutics and is the leader in the use of somatic hypermutation (SHM) for antibody discovery and optimization. We are developing a pipeline of novel therapeutic antibody candidates, including differentiated programs in cancer immunotherapy, inflammation, fibrosis, muscle wasting disorders and antibody-drug conjugate applications.  AnaptysBio’s proprietary SHM-XEL™ platform, which couples fully human antibody libraries with in vitro somatic hypermutation in mammalian cells to generate high affinity antibodies, replicates key features of the human immune system and overcomes limitations of prior antibody technologies.  By harnessing the natural mechanism of antibody maturation under controlled conditions, SHM-XEL allows for the selection of optimal antibody properties such as high affinity, stability, function, cross-reactivity, epitope diversity and manufacturability. The Company has previously announced partnerships with Merck, Roche, Novartis, Celgene, Gilead, Momenta, DARPA and DTRA.  Major investors in AnaptysBio include Alloy Ventures, Avalon Ventures, Frazier Healthcare Ventures and Novo A/S.  For more information, visit www.anaptysbio.com.

(CPST) Follow-on Orders for Fifty C65s Destined For Multiple U.S. Oil and Gas Customers

CHATSWORTH, Calif., March 12, 2014  — Capstone Turbine Corporation (www.capstoneturbine.com) (Nasdaq:CPST), the world’s leading clean technology manufacturer of microturbine energy systems, announced today it received orders for fifty Capstone C65 microturbines for oil and gas production in the United States.

Horizon Power Systems, Capstone’s exclusive oil and gas distributor for the Eagle Ford, Permian, San Juan and Wattenberg Shale plays, secured the orders to support the growing power needs of its existing customers. The orders will bring the total fleet to more than 550 microturbines in operation in Horizon’s area of responsibility and will serve various stages of oil and gas production including powering central processing stations, well-head operation, and flare reduction.

“North American shale gas producers continue to adopt Capstone microturbines because they want the high reliability and low emission benefits of our products,” said Sam Henry, President of Horizon Power Systems. “Additionally, customers are committed to conducting business safely, in a socially and environmentally responsible manner, which is precisely what Capstone microturbines deliver.”

Capstone continues its rapid penetration of the North American shale gas market with these follow on orders. These orders help demonstrate that Capstone’s low emission, durable, and highly efficient microturbines are the preferred choice for around-the-clock production and optimized well site performance. Capstone’s low maintenance ensures a higher availability than its competitors and also reduces operational costs.

“The oil and gas market continues to show steady growth worldwide,” said Jim Crouse, Capstone’s Executive Vice President of Sales and Marketing. “Capstone microturbines have become the go to power source for producers that want extremely reliable, easy to deploy and low emission onsite power solutions. The repeat order indicates our customers’ satisfaction with our clean and green solutions.”

About Capstone Turbine Corporation

Capstone Turbine Corporation (www.capstoneturbine.com) (Nasdaq:CPST) is the world’s leading producer of low-emission microturbine systems and was the first to market commercially viable microturbine energy products. Capstone Turbine has shipped approximately 7,000 Capstone Microturbine systems to customers worldwide. These award-winning systems have logged millions of documented runtime operating hours. Capstone Turbine is a member of the U.S. Environmental Protection Agency’s Combined Heat and Power Partnership, which is committed to improving the efficiency of the nation’s energy infrastructure and reducing emissions of pollutants and greenhouse gases. A UL-Certified ISO 9001:2008 and ISO 14001:2004 certified company, Capstone is headquartered in the Los Angeles area with sales and/or service centers in the New York Metro Area, United Kingdom, Mexico City, Shanghai and Singapore.

The Capstone Turbine Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6212

This press release contains “forward-looking statements,” as that term is used in the federal securities laws, about the environmental advantages and reliability of our products and the use of our products in the oil and gas market. Forward-looking statements may be identified by words such as “expects,” “objective,” “intend,” “targeted,” “plan” and similar phrases. These forward-looking statements are subject to numerous assumptions, risks and uncertainties described in Capstone’s filings with the Securities and Exchange Commission that may cause Capstone’s actual results to be materially different from any future results expressed or implied in such statements. Capstone cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Capstone undertakes no obligation, and specifically disclaims any obligation, to release any revisions to any forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

“Capstone” and “Capstone MicroTurbine” are registered trademarks of Capstone Turbine Corporation. All other trademarks mentioned are the property of their respective owners.

CONTACT: Capstone Turbine Corporation
         Investor and investment media inquiries:
         818-407-3628
         ir@capstoneturbine.com

(UBNT) Crowne Plaza Hickory Builds a Superior Hotel Network With Ubiquiti

(AQXP) Announces Closing of Initial Public Offering

Full Exercise of Underwriters’ Option to Purchase Additional Shares for Aggregate Offering Price of $53.1 Million

VANCOUVER, British Columbia, March 12, 2014  — Aquinox Pharmaceuticals, Inc. (Nasdaq:AQXP) announced today the closing of its initial public offering of 4,830,000 shares of its common stock at a public offering price of $11.00, which included 630,000 shares issued upon the exercise in full of the underwriters’ option to purchase additional shares. All of the shares of common stock were offered by Aquinox. The aggregate offering price was $53.1 million, before underwriting discounts, commissions and estimated expenses. The net proceeds from the sale of the shares, after deducting the underwriting discounts, commissions and other estimated offering expenses, will be approximately $47.0 million.

Jefferies LLC and Cowen and Company acted as joint book-running managers and Canaccord Genuity acted as co-manager for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on March 6, 2014. The offering was made only by means of a prospectus, final copies of which may be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12^th Floor, New York, NY 10022, telephone: 877-547-6340, e-mail: Prospectus_Department@Jefferies.com; or Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, Telephone: 631-274-2806, Fax: 631-254-7140.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Aquinox Pharmaceuticals

Aquinox Pharmaceuticals, Inc. (“Aquinox”) is a clinical stage pharmaceutical company discovering and developing novel, small molecule therapeutics targeting SH2-containing inositol-5′-phosphatase 1 (“SHIP1“) for the treatment of inflammatory disease and cancer. For more information, please visit www.aqxpharma.com.

CONTACT: Kamran Alam, VP Finance and CFO
         Aquinox Pharmaceuticals, Inc.
         604.629.9223
         ir@aqxpharma.com

         Jason Robertson, Director, Business Development
         Aquinox Pharmaceuticals Inc.
         604.629.9223
         info@aqxpharma.com

(GORO) Intercepts 2.67M of 13.90 G/T Gold, 3,228 G/T Silver in New Vein at Arista

Gold Resource Corporation (NYSE MKT: GORO) (the “Company”) announces an Arista deposit exploration update at its El Aguila Project in Mexico. Drill results included 2.67 meters of 13.90 grams per tonne gold and 3,228 grams per tonne silver in one of the Arista deposit’s newest vein discoveries. Gold Resource Corporation is a gold and silver producer with operations in the southern state of Oaxaca, Mexico. The Company has returned over $95 million to shareholders in monthly dividends since declaring production July 1, 2010, and offers shareholders the option to convert their cash dividends into physical gold and silver and take delivery.

The Company continues to drill both infill and step-out holes testing the mineralized vein extensions at its producing Arista mine. The Arista is a high-grade polymetallic (gold, silver and base metal) epithermal vein deposit with multiple parallel en echelon veins. Drilling at a recently discovered vein, referred to as the “Santa Lucia” vein (see map), intercepted high-grade mineralization including 2.67 meters grading 13.90 grams per tonne (g/t) gold, 3,228 g/t silver, 1.32% copper, 0.95% lead and 1.61% zinc, including 0.46 meters grading 65.20 g/t gold, 18,232 g/t silver, 6.52% copper, 4.59% lead and 6.75% zinc. The Santa Lucia vein is a parallel vein structure located approximately 60 meters northeast of the Arista vein on level 14. Santa Lucia remains open on strike and at depth.

Additional drill highlights include the Candelaria and Luz veins, located southwest of the Baja vein. The Luz vein returned results as high as 1.87 meters grading 6.16 g/t gold, 321 g/t silver, 0.97% copper, 2.12% lead and 4.35% zinc. Candelaria returned 3.02 meters grading 9.51 g/t gold, 2,702 g/t silver, 0.35% copper, 0.75% lead and 1.31% zinc, including 0.77 meters grading 25.50 g/t gold, 5,310 g/t silver, 0.77% copper, 0.75% lead and 2.47% zinc. These veins also remain open along strike and at depth.

New drilling at the Baja vein, one of two original veins in production since 2011, returned results as high as 0.92 meters of 28.10 g/t gold, 116 g/t silver, 0.77% copper, 7.55% lead and 9.85% zinc. This vein continues to deliver notable grades and production tonnes and is still open along strike and at depth.

“The Arista system continues to deliver impressive grades and expansion potential,” stated Gold Resource Corporation’s CEO and President, Mr. Jason Reid. “Our original deposit model projected two primary veins, the Baja and Arista. Drilling continues to expand the deposit at depth, along strike as well as parallel to the main structure. With the deposit expanding south towards the Splay 5 and Socorro veins, along with our discovery at Switchback, 500 meters to the northeast of the Arista deposit, we are very impressed with the system’s continued expansion potential. We believe we are in a strong position to continue adding ounces to this high-grade polymetallic deposit, with the goal of having three to four years production drilled out in front of us at any point in time.”

Gold Resource Corporation Vice President of Exploration, Mr. Barry Devlin added, “When we first started production in the Arista underground mine, we were mining the Arista and Baja veins together with just a few minor veins and splays. Now we have modeled 20 different mineralized primary veins, minor veins and splays. The Arista deposit appears to be a very robust epithermal vein system like those found in the famous Zacatecas and Fresnillo districts of Mexico.”

About GRC:
Gold Resource Corporation is a mining company focused on production and pursuing development of gold and silver projects that feature low operating costs and produce high returns on capital. The Company has 100% interest in six potential high-grade gold and silver properties in Mexico’s southern state of Oaxaca. The Company has 54,179,369 shares outstanding, no warrants and no debt. Gold Resource Corporation offers shareholders the option to convert their cash dividends into physical gold and silver and take delivery. For more information, please visit GRC’s website, located at www.Goldresourcecorp.com and read the Company’s 10-K for an understanding of the risk factors involved.

Cautionary Statements:
This press release contains forward-looking statements that involve risks and uncertainties. The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. When used in this press release, the words “plan”, “target”, “anticipate,” “believe,” “estimate,” “intend” and “expect” and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements include, without limitation, the statements regarding Gold Resource Corporation’s strategy, future plans for production, future expenses and costs, future liquidity and capital resources, and estimates of mineralized material. All forward-looking statements in this press release are based upon information available to Gold Resource Corporation on the date of this press release, and the company assumes no obligation to update any such forward-looking statements. Forward looking statements involve a number of risks and uncertainties, and there can be no assurance that such statements will prove to be accurate. The Company’s actual results could differ materially from those discussed in this press release. In particular, there can be no assurance that production will continue at any specific rate. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the Company’s 10-K filed with the SEC.

Contacts:
Corporate Development
Greg Patterson
303-320-7708
www.Goldresourcecorp.com

(ABIO) Dan Mitchell Joins ARCA biopharma Board of Directors

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that Dan Mitchell has been appointed to the Company’s Board of Directors. He will serve on the Audit and Nominating and Corporate Governance Committees of the Board of Directors.

Mr. Mitchell founded and is a Manager of Sequel Venture Partners, L.L.C., a venture capital firm formed in January 1997. Prior to founding Sequel Venture Partners, Mr. Mitchell was a founder in 1986 of Capital Health Venture Partners, a health care focused venture capital firm, where he was a General Partner until 2006. On behalf of Sequel Ventures, Mr. Mitchell led the 1998 Series A financing that initially funded Myogen, Inc., a biopharmaceutical company focused on cardiovascular diseases, participated in subsequent financing rounds and served on the board of directors until Myogen’s was acquired in 2006. He served on the board of directors of Replidyne, Inc., a publicly traded pharmaceutical company, from 2002 until the company was acquired in 2009. Mr. Mitchell currently serves on the board of directors of several private companies. Mr. Mitchell holds a B.S. from the University of Illinois and an M.B.A. from the University of California at Berkeley.

“We are honored to have Dan join the ARCA Board of Directors,” said Dr. Michael R. Bristow, President and Chief Executive Officer of ARCA. “With his significant expertise and experience in identifying investment worthy companies and helping to advise those companies in managing their growth, Dan will be a valuable addition to the ARCA Board as we continue the development of Gencaro and look to deliver value to our stockholders.”

“I am delighted to join the Board of ARCA at this important point in its development,” said Mr. Mitchell. “The imminent initiation of the GENETIC-AF trial evaluating ARCA’s Gencaro as potentially the first genetically-targeted atrial fibrillation prevention treatment is a tremendous step in hopefully addressing what we believe is an unmet medical need for new atrial fibrillation treatments. ARCA’s personalized medicine approach to drug development has identified both the compound and the regulatory pathway to potentially achieve that goal.”

About ARCA biopharma

ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate, Gencaro^TM (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with Medtronic, Inc. for support of the GENETIC-AF trial. For more information please visit www.arcabiopharma.com.

Safe Harbor Statement

This press release contains “forward-looking statements” for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding, potential timing for patient enrollment in the GENETIC-AF trial, the sufficiency of the Company’s capital to support its operations, the potential for genetic variations to predict individual patient response to Gencaro, Gencaro’s potential to treat atrial fibrillation, future treatment options for patients with atrial fibrillation, the role of AF burden in diagnosis and treatment of atrial fibrillation and the potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention treatment. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company’s financial resources and whether they will be sufficient to meet the Company’s business objectives and operational requirements; results of earlier clinical trials may not be confirmed in future trials, the protection and market exclusivity provided by the Company’s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA’s filings with the SEC, including without limitation the Company’s annual report on Form 10-K for the year ended December 31, 2012, and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements.

(MTSL) Announces Filing of 2013 Annual Report

RA’ANANA, Israel, March 12, 2014  — MTS – Mer Telemanagement Solutions Ltd. (NASDAQ Capital Market: MTSL), a global provider of MVNE, Mobile Money and TEM services, today announced that it has filed its annual report containing audited consolidated financial statements for the year ended December 31, 2013 with the U.S. Securities and Exchange Commission.  The annual report is available on the Company’s website (www.mtsint.com).  Shareholders may receive a hard copy of the annual report free of charge upon request.

Mer Telemanagement Solutions Ltd. (MTS) is a worldwide provider of innovative products and services for Telecom Expense Management (TEM), Enterprise Mobility Management (EMM), Mobile Virtual Network Operators and Enablers (MVNO/MVNE) and Mobile Money services and solutions used by mobile service providers.

About MTS

The MTS TEM Suite solution enables enterprises to gain visibility and control of strategic fixed and mobile telecom assets, services and IT security policies that drive key business processes and crucial competitive advantage. The MTS cloud, consulting and managed services solutions — including integrated management of invoices, assets, wireless, optimization, usage, mobile device management, procurement, help desk and bill payment, along with dashboards and reporting tools — provide professionals at every level of the organization with rapid access to concise, actionable data.

MTS’s solutions for telecommunication service providers are used worldwide by wireless and wireline service providers for interconnect billing, partner revenue management and for charging and invoicing their customers. MTS provides MVNE services to allow the quick launch of new MVNO initiatives in a pay as you grow and revenue share models. In addition, MTS has pre-configured solutions to support emerging carriers of focused solutions (e.g. IPTV, VoIP, WiMAX, MVNO) to rapidly install a full-featured and scalable solution.

Headquartered in Israel, MTS markets its solutions through wholly owned subsidiaries in the United States and Hong Kong and through distribution channels. MTS shares are traded on the NASDAQ Capital Market (symbol MTSL). For more information please visit the MTS web site: www.mtsint.com.

Certain matters discussed in this news release are forward-looking statements that involve a number of risks and uncertainties including, but not limited to, risks in product development plans and schedules, rapid technological change, changes and delays in product approval and introduction, customer acceptance of new products, the impact of competitive products and pricing, market acceptance, the lengthy sales cycle, proprietary rights of the Company and its competitors, risk of operations in Israel, government regulations, dependence on third parties to manufacture products, general economic conditions and other risk factors detailed in the Company’s filings with the United States Securities and Exchange Commission.

(ABCB) Announces Acquisition of Coastal Bankshares, Inc.

MOULTRIE, Ga. and SAVANNAH, Ga., March 11, 2014  — Ameris Bancorp (“Ameris”), the parent company of Ameris Bank, announced today the signing of a definitive merger agreement under which Ameris will acquire Coastal Bankshares, Inc. (“Coastal”), the parent company of The Coastal Bank, Savannah, Georgia.  As of December 31, 2013, Coastal reported assets of $433 million, loans of $295 million, and deposits of $364 million.  Upon completion of the transaction, the combined company will have approximately $4.1 billion in assets, $2.8 billion in loans, $3.4 billion in deposits and a branch network of 74 banking locations across four states.

The acquisition significantly enhances Ameris’s current franchise in the greater Savannah marketplace.  Coastal currently operates six branches, five of which are concentrated in the Savannah, Georgia Metropolitan Statistical Area (“MSA”) and one of which is located in the Hinesville, Georgia MSA.  Coastal also operates mortgage loan production offices in Richmond Hill and Statesboro, Georgia.  After the acquisition, Ameris will advance from twelfth to fifth in deposit market share in the Savannah market.

“We are excited to announce our merger with Coastal and are looking forward to welcoming the Coastal team to Ameris,” said Edwin W. Hortman, Jr., President and Chief Executive Officer of Ameris.  “We believe our combined efforts in the Savannah market will result in even greater service for our customers.”

“Coastal Bank is pleased to form a partnership with Ameris.  We believe this combination serves the best interest of our shareholders, customers, employees and community,” commented James A. LaHaise, President and Chief Executive Officer of Coastal. “We view Ameris as one of the leading community banks in both Georgia and the Southeast.  The compatible nature of our cultures will provide great benefits to the Savannah banking market.”

Under the terms of the merger agreement, Coastal shareholders will receive 0.4671 shares of Ameris common stock for each share of Coastal common stock.  The transaction is valued at approximately $36.7 million in the aggregate, or $10.00 per Coastal share, based on Ameris’s average closing stock price of $21.41 for the three days ending March 7, 2014.

The merger agreement has been unanimously approved by the board of directors of each company.  The transaction is expected to close early in the third quarter of 2014 and is subject to customary closing conditions, regulatory approvals and approval by Coastal shareholders.

Keefe, Bruyette & Woods, Inc. served as financial advisor and Rogers & Hardin LLP provided legal counsel to Ameris.  Banks Street Partners, LLC served as financial advisor and Troutman Sanders LLP provided legal counsel to Coastal.

Conference Call Information

Ameris Bancorp will host a conference call and webcast today at 10:00 a.m. EDT. The conference call can be accessed by dialing 1-888-317-6016 or 1-412-317-6016 for international participants. A replay of the call will be available one hour after the end of the conference call until March 19th at 9:00 a.m. EDT. To listen to the replay, dial 1-877-344-7529 or 1-412-317-0088. The conference number is 10042630. The webcast will also be available on the Investor Relations page of www.amerisbank.com.

Ameris Bancorp

Ameris Bancorp is headquartered in Moultrie, Georgia, and at the end of the most recent quarter had 68 locations in Georgia, Alabama, northern Florida and South Carolina.

A presentation with additional information regarding the transaction will be available on the Investor Relations page of www.amerisbank.com.

Additional Information About the Merger

Shareholders of Coastal and other investors are urged to read the proxy statement/prospectus that will be included in the registration statement on Form S-4 that Ameris will file with the Securities and Exchange Commission in connection with the proposed merger.

Forward-Looking Statements

This news release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “believe”, “estimate”, “expect”, “intend”, “anticipate” and similar expressions and variations thereof identify certain of such forward-looking statements, which speak only as of the dates which they were made. Ameris Bancorp (the “Company”) undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and that actual results may differ materially from those indicated in the forward-looking statements as a result of various factors. Readers are cautioned not to place undue reliance on these forward-looking statements and are referred to the Company’s periodic filings with the Securities and Exchange Commission for a summary of certain factors that may impact the Company’s results of operations and financial condition.

(RDCM) Strong Momentum with its MaveriQ Solution; Multi-million Dollar LTE Deal in Brazil

TEL AVIV, Israel, March 11, 2014  — RADCOM Ltd. (NASDAQ: RDCM) a leading innovative customer experience and service assurance provider, today announced the initial phase of a multi-year deal at the approximate amount of $3.5M with a major operator in Brazil. This deal will cover the operator’s 3G and LTE network providing new agility that reduces OPEX and CAPEX.

This tier 1 Brazilian Cellular operator purchased RADCOM’s system to provide service assurance for their Mobile broadband 3G and LTE network. RADCOM offered this operator one solution for different technologies running on the recently announced, powerful cost-effective terabit MaveriQ probes. This operator is experiencing a rapid increase in traffic; consequently, following their own expansion to LTE they purchased RADCOM’s MaveriQ solution and applications to help them continue to provide high quality of service to their customers.

“We are excited by the momentum generated by our MaveriQ technology, a powerful service assurance solution which confirmed RADCOM’s advantage over the competition,” said Mr. David Ripstein RADCOM’s CEO. “This deal is a realization of our business strategy which concentrates on increasing our hold in LATAM and APAC markets and the shift we made to a software-based solution, ready for NFV (Network Functionality Virtualization).”

About RADCOM

RADCOM provides innovative service assurance and customer experience management solutions for leading telecom operators and communications service providers. RADCOM specializes in solutions for next-generation mobile and fixed networks, including LTE, VoLTE, IMS, VoIP, UMTS/GSM and mobile broadband. RADCOM’s comprehensive, carrier-grade solutions are designed for big data analytics on terabit networks, and are used to prevent service provider revenue leakage and to enhance customer care management. RADCOM’s products interact with policy management to provide self-optimizing network solutions. RADCOM’s shares are listed on the NASDAQ Capital Market under the symbol RDCM. . For more information, please visit www.RADCOM.com.

Risks Regarding Forward-Looking Statements

Certain statements made herein that use the words “estimate,” “project,” “intend,” “expect,” “believe” and similar expressions are intended to identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties that could cause the actual results, performance or achievements of RADCOM to be materially different from those that may be expressed or implied by such statements, including, among others, changes in general economic and business conditions and specifically, decline in the demand for RADCOM’s products, inability to timely develop and introduce new technologies, products and applications, and loss of market share and pressure on prices resulting from competition. For additional information regarding these and other risks and uncertainties associated with RADCOM’s business, reference is made to RADCOM’s reports filed from time to time with the United States Securities and Exchange Commission. RADCOM does not undertake to revise or update any forward-looking statements for any reason.

Contact: 
Eyal Harari
VP Products and Marketing
+972-77-774-5030
eyalh@radcom.com

(LOCM) Launches Where-to-Buy Solution for Manufacturers Powered by Krillion®

Local Corporation (NASDAQ: LOCM), a leading local advertising and technology company, today announced the launch of its new Where-to-Buy solution for manufacturers, powered by the company’s enterprise-ready Krillion® local shopping platform.

The new Where-to-Buy solution enables product manufacturers of all sizes to drive more sales by connecting shoppers engaged in online pre-purchase research directly with preferred local retailers. The solution is easy to implement and available to thousands of consumer brands maintained in the Krillion data index.

The full-featured solution leverages Krillion’s localization engine to provide location-based product, brand and store-level information to consumers through a turn-key JavaScript® integration on manufacturer product detail pages. Unlike other solutions of its kind, Local Corporation’s Where-to-Buy solution delivers dynamic pricing and real-time stock availability.

Features for manufacturers include:

• Responsive design for mobile and desktop
• Real-time stock availability checks
• Dynamic pricing updates
• Rich store-level details, including hours and maps
• On-demand regional traffic reporting

Where-to-Buy is also offered as a customized API solution via data license allowing manufacturers to drive shoppers to retailers through their brand’s website, mobile sites and apps, social channels and rich media ads.

“Product shopping research via smartphone grew to 73 percent in 2013¹. Manufacturers need to take advantage of this behavior and deliver the critical product data that mobile shoppers rely on along the path to purchase,” said Michael Sawtell, president and COO, Local Corporation.

“Manufacturers are continually looking for new ways to drive sales from their brand websites,” added Sawtell. “Our Where-to-Buy solution makes it easy for shoppers to find and buy products from local retailers, greatly increasing their brand exposure and driving more purchases both online and offline.”

Krillion’s local shopping platform aggregates dynamic, national and regional retail shopping content, from approximately 120,000 store locations covering 90 percent of the top 100 national retailers, representing nearly 3 million localized products. The company will be showcasing its new Where-to-Buy solution and other exciting initiatives at ad:tech San Francisco (booth #2418), March 26-27, 2014.

For more information on the Where-to-Buy solution, visit: http://about.krillion.com/Manufacturers.

About Local Corporation

Local Corporation (NASDAQ:LOCM) is a leading local advertising and technology company that connects businesses with approximately a million online and mobile consumers each day using a variety of innovative digital advertising products. For more information, visit: http://www.localcorporation.com.

¹ Local Corporation and the e-tailing group, September 2013

JavaScript is a trademark or registered trademark of Oracle in the U.S. and other countries.

Forward Looking Statements

This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Words or expressions such as “anticipate,” “plan,” “will,” “intend,” “believe” or “expect'” or variations of such words and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Key risks are described in the filings we make with the U.S. Securities and Exchange Commission. The forward-looking statements in this release speak only as of the date they are made. We undertake no obligation to revise or update publicly any forward-looking statement for any reason. Unless otherwise stated, all site traffic and usage statistics are from third-party service providers engaged by the company. Traffic and our monetization of that traffic combine to determine our revenues for any given period. Our traffic volume alone for a period should not be viewed as demonstrative of our financial results for such period.

(OXGN) Topline Results Phase 2 ZYBRESTAT® In Recurrent Ovarian Cancer

Trial Achieves Primary Efficacy Endpoint of a Statistically Significant Reduction in Progression-Free Survival

SOUTH SAN FRANCISCO, Calif., March 11, 2014  — OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced positive results from a randomized Phase 2 clinical trial evaluating Avastin^® (bevacizumab) with or without ZYBRESTAT^® (fosbretabulin; CA4P) to treat patients with recurrent ovarian cancer. The study, known as Gynecologic Oncology Group protocol 186I, met its primary endpoint of a statistically significant increase in progression-free survival (p < 0.05; hazard ratio 0.685) for the combination as compared to bevacizumab alone.

The Phase 2 study is being conducted by the GOG under the sponsorship of the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI). It is the first and currently only randomized trial to test an antiangiogenic therapeutic agent combined with a vascular disrupting agent, without including any cytotoxic chemotherapy.

“These findings validate both the novel approach and the complementary mechanisms of combining the vascular disrupting agent fosbretabulin and an antiangiogenic agent like bevacizumab in patients with ovarian cancer,” said Bradley J. Monk, M.D., FACS, FACOG, principal investigator for the trial, and professor and director, Division of Gynecologic Oncology and Department of Obstetrics and Gynecology at the University of Arizona Cancer Center. “This promising combination warrants further evaluation particularly given the significant need for new treatment options in relapsed ovarian cancer.”

As previously reported, the GOG protocol 186I enrolled 107 patients with platinum-sensitive and -resistant recurrent ovarian cancer at 67 clinical sites in the U.S. Patients were randomized 1:1 into one of two treatment arms: one arm received Avastin, and the second arm received Avastin plus ZYBRESTAT. Both therapies were administered intravenously every three weeks and patients were treated until disease progression or until adverse effects prohibited further therapy.

Secondary endpoints in the study include safety, objective response rate (measured according to RECIST criteria) and overall survival. Patients receiving the combination of ZYBRESTAT and Avastin achieved a higher objective response rate, which was not statistically significant. All patients will continue to be followed for overall survival. Consistent with prior clinical experience with ZYBRESTAT, patients in the combination arm experienced a higher incidence of hypertension compared to the control arm.  All cases of hypertension were managed with antihypertensive treatments, as specified in the study protocol. It is expected that the full study results will be submitted for presentation at a future scientific meeting.

For this study, ZYBRESTAT is provided to CTEP under a Cooperative Research and Development Agreement (CRADA) with OXiGENE and bevacizumab is being provided as an investigational agent under a CRADA with Genentech. Bevacizumab is not approved to treat women with ovarian cancer in the U.S.; however, it is approved in other countries for treatment of ovarian cancer.

“We are very excited about these positive results and greatly appreciate all the patients who enrolled in this study and the support, resources and commitment of GOG and CTEP to conduct this important program,” said Peter Langecker, M.D., Ph.D., chief executive officer of OXiGENE. “ZYBRESTAT is the first vascular disrupting agent to show a statistically significant progression-free survival benefit, and we are evaluating next steps to advance this combination to patients in need.”

About ZYBRESTAT^®

ZYBRESTAT (fosbretabulin tromethamine/combretastatin-A4 phosphate / CA4P) is OXiGENE’s lead vascular disrupting agent (VDA) product candidate, and is currently being evaluated as a treatment for solid tumors. ZYBRESTAT exerts its antitumor effects through the validated therapeutic mechanism of tumor blood supply deprivation. By selectively affecting and disabling tumor vasculature, ZYBRESTAT reduces the blood supply necessary for tumor growth and survival. The resulting oxygen starvation and build-up of tumor metabolic by-products causes the cancer cells within the central core of the tumor to die.

About the Gynecologic Oncology Group

The Gynecologic Oncology Group (GOG) is a not-for-profit organization with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of gynecologic malignancies. The GOG is committed to maintaining the highest standards in clinical trials development, execution, analysis and distribution of results. The GOG is one of the National Cancer Institute’s funded cooperative groups. The GOG is the only group that focuses its research on women with pelvic malignancies, such as cancer of the ovary, uterus, and cervix. The GOG is multi-disciplinary in its approach to clinical trials, and includes gynecologic oncologists, medical oncologists, pathologists, radiation oncologists, nurses, statisticians, basic scientists, quality of life experts, data managers, and administrative personnel.

About OXiGENE

OXiGENE is a biopharmaceutical company developing novel therapeutics to treat cancer. The Company is focused on developing vascular disrupting agents (VDAs), which are compounds that selectively disrupt abnormal blood vessels associated with solid tumor survival and progression. The Company’s lead clinical product candidate, ZYBRESTAT^®, is in development for solid tumors. OXi4503, its second-generation product candidate, is in development for acute myeloid leukemia (AML). OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.

Safe Harbor Statement

This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release, which include the timing of advancement, outcomes, data and regulatory guidance relative to its clinical programs and achievement of our business and financing objectives may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to, the inherent risks of drug development, manufacturing and regulatory review, and the availability of additional financing to continue development of its programs. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE’s reports to the Securities and Exchange Commission, including OXiGENE’s reports on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2012.

CONTACT: Investor and Media Contact:
         ir@oxigene.com
         650-635-7000

(CDTI) Announces New Honda Vehicle Award

VENTURA, Calif., March 11, 2014  — Clean Diesel Technologies, Inc. (Nasdaq:CDTI) (“CDTi” or the “Company”), a leader in advanced emissions control solutions, announced that it has begun production of catalysts featuring CDTi’s high-performance Mixed Phase Catalyst (MPC^®) technology for Honda’s 2015 Acura TLX model. Shipments are expected to commence in the first half of 2014.

Along with the Acura TLX, CDTi also provides its catalyst solutions to Honda for North American versions of their four- and six-cylinder Accord, Acura TSX and RLX, as well as Hybrid and Plug-In Hybrid models.

The MPC^® design is focused on superior thermal stability, giving its catalyst products critical attributes that differentiate them from competing offerings:

• Significantly improved performance for a given level of precious metals — to meet increasingly stringent emissions standards and powertrain diversification; and
• Greatly reduced precious metal loadings to achieve a given emission standard.

“We are proud to be named Honda’s catalyst supplier for the 2015 Acura TLX. Having our advanced catalyst technologies on a growing number of Honda vehicle platforms—currently 6— is a testament to CDTi’s ability to provide market-leading solutions to our customers. The demand for greater emission reduction continues to grow across all vehicle segments as evidenced by the recent U.S. Environmental Protection Agency’s announcement of Tier 3 standards. Our MPC^® technology is well suited to meet this trend. We are continually evolving our technologies to assure our customers are supplied with catalyst products that give them sustainable performance and cost advantage in the highly competitive environment they face,” said Nikhil Mehta, Office of the CEO and Chief Financial Officer.

CDTi’s Catalyst division began delivering catalysts to Honda in 2001 — offering a unique combination of high performance and low platinum group metal content, resulting in significant economic benefits. Since then, CDTi’s catalysts have been sourced for new model programs that typically span four to five years, including the popular model years 2004, 2008 and 2013 Accord as well as other existing and new Honda models.

About CDTi

CDTi is a vertically integrated global manufacturer and distributor of emissions control systems and products, focused on the heavy duty diesel and light duty vehicle markets. CDTi utilizes its proprietary patented Mixed Phase Catalyst (MPC^®) technology, as well as its ARIS^® selective catalytic reduction, Platinum Plus^® fuel-borne catalyst, and other related technologies to provide high-value sustainable solutions to reduce emissions, increase energy efficiency and lower the carbon intensity of on- and off-road combustion engine systems. CDTi is headquartered in Ventura, California and currently has operations in the U.S., Canada, France, Japan and Sweden. For more information, please visit www.cdti.com.

Forward-Looking Statements Safe Harbor

Certain information contained in this press release constitutes forward-looking statements. Any statements contained herein that are not statements of historical fact should be considered forward-looking statements, and include in this press release statements regarding product attributes, sourcing, and expected shipments, CDTi’s relationship with Honda, and technology trends. Forward-looking statements involve known or unknown risks, including, without limitation, the potential inability of CDTi’s products to evolve, remain attractive to customers, or meet evolving standards or trends, the possible loss of CDTi’s status as a named Honda supplier, unforeseen difficulties or delays in CDTi’s ability to supply its products, the slowdown or stoppage of demand for emission reduction technologies, and the inability of CDTi to source its products for new model programs. In addition, reference is made to the risks detailed in CDTi’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date made. CDTi assumes no obligation to update the forward-looking information contained in this press release.

CONTACT: Kevin M. McGrath
         Cameron Associates, Inc.
         Tel: +1 (212) 245-4577

(CUI) Sets Performance Benchmarks with the Release of a 60A Digital POL Series

TUALATIN, Ore., March 10, 2014  — CUI Global, Inc. (NASDAQ:CUI), a platform company dedicated to the acquisition, development, and commercialization of new, innovative products and technologies, today announced that its wholly owned subsidiary, CUI Inc, has released a new family of digital point of load dc-dc modules that set performance benchmarks in efficiency, power density, and transient response to address the rapidly-rising power challenges in distributed power architectures.  The NDM3ZS-60 is a non-isolated module outputting 60A in ultra low-profile vertical and horizontal packages. The series is the first non-isolated design to incorporate CUI’s patented Solus® Power Topology which integrates a conventional buck converter into a SEPIC converter to form a SEPIC-fed buck converter. The topology is able to reduce switching turn-on losses by 75% and switching turn-off losses by 99% on the control FET when compared to a conventional buck converter. The Solus Topology further increases total efficiency by distributing the energy delivery into multiple paths, reducing circuit conduction losses by nearly 50%.  The new topology allows the NDM3ZS-60 to hit the performance metrics quickly which is imperative in today’s advanced designs.

“We are very excited to announce the release of our first non-isolated POL module based on the Solus Power Topology,” said Matt McKenzie, CUI’s president. “Our networking customers have hit a ceiling with existing POL topologies as the challenges of powering today’s advanced ICs have increased. Our NDM3ZS-60 addresses these efficiency, power density, and transient challenges head-on.”

CUI Global’s president & CEO, William Clough, stated that, “According to IHS, a global information company, the world market for digital power is expected to be worth $12.4 billion by 2017.  Our Novum® Advanced Power line continues to push the envelope in intelligent power management, solidifying CUI’s position as a leader in this rapidly-expanding market segment.”

Learn more about the NDM3ZS-60 and the rest of CUI’s Novum Advanced Power line at this year’s Applied Power Electronics Conference (APEC) show in Fort Worth, Texas, running from March 16th to the 20th. CUI Inc will be located at booth 1233, and will demonstrate their lineup of advanced power modules, including advanced intermediate bus and digital point of load dc-dc converters.

About CUI Global, Inc.
Delivering Innovative Technologies for an Interconnected World . . . . .
CUI Global, Inc. is a publicly traded company dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies. From Orbital Gas Systems’ advanced GasPT2 platform targeting the energy sector, to CUI Inc’s digital power platform serving the networking and telecom space, CUI Global and its subsidiaries have built a diversified portfolio of industry leading technologies that touch many markets. As a publicly traded company, shareholders are able to participate in the opportunities, revenues, and profits generated by the products, technologies, and market channels of CUI Global and its subsidiaries. But most importantly, a commitment to conduct business with a high level of integrity, respect, and philanthropic dedication allows the organization to make a difference in the lives of their customers, employees, investors and global community.

For more information please visit www.cuiglobal.com

About CUI Inc
CUI Inc is a technology company dedicated to the development, commercialization, and distribution of new, innovative electro-mechanical products. Over the past 20 years, CUI has become a recognized name in electronic components worldwide in the areas of power, interconnect, motion control, and sound. CUI’s solid customer commitment and honest corporate message are a hallmark in the industry. CUI is a wholly owned subsidiary of CUI Global, Inc.

For more information, please visit www.cui.com.

Important Cautions Regarding Forward Looking Statements
This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties that could cause actual results to vary materially from those projected in the forward-looking statements. The company may experience significant fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, our reliance on third-party manufacturers and suppliers, government agency budgetary and political constraints, new or increased competition, changes in market demand, and the performance or reliability of our products. These factors and others could cause operating results to vary significantly from those in prior periods, and those projected in forward-looking statements. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in certain forms the company has filed with the Securities and Exchange Commission.

(OHRP) to Present at the 26th Annual ROTH Conference

NEW YORK, March 10, 2014  — Ohr Pharmaceutical (Nasdaq:OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced that Irach Taraporewala, Ph.D., Chief Executive Officer and President, will present a corporate overview and business update at the 26^th Annual ROTH Conference, being held at the Ritz Carlton in Dana Point, California from March 9-12, 2014.

The ROTH Conference is organized by ROTH Capital Partners. For more information, please go to www.roth.com.

About Ohr Pharmaceutical Inc.

Ohr Pharmaceutical Inc. (OHRP) is a pharmaceutical company dedicated to the clinical development of new drugs for underserved therapeutic needs in large and growing markets. The Company is focused on advancing its pipeline products currently in phase II clinical development: Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration, and OHR/AVR118 for the treatment of cancer cachexia. Additional information on the company can be found at www.ohrpharmaceutical.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: 
This news release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and Ohr Pharmaceutical undertakes no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, the financial resources available to us, and general economic conditions. Shareholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can be claimed or assured until final testing; and no assurance or warranty can be made that the FDA or Health Canada will approve final testing or marketing of any pharmaceutical product. Ohr’s most recent Annual Report and subsequent Quarterly Reports discuss some of the important risk factors that may affect our business, results of operations and financial condition. We disclaim any intent to revise or update publicly any forward-looking statements for any reason.

CONTACT: Ohr Pharmaceutical Inc.
         Investor Relations
         (877) 215-4813
         ir@ohrpharmaceutical.com

         LifeSci Advisors, LLC
         Michael Rice
         646-597-6987
         mrice@lifesciadvisors.com

(NWBO) 2 German Approvals: “Hospital Exemption” for Early Access Program, DCVax-L

DCVax-L Is First Product of Its Kind to Receive Hospital Exemption from German Regulator

BETHESDA, Md., March 10, 2014  — Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has received approval from the Paul Ehrlich Institute (“PEI”- the FDA of Germany) of a “Hospital Exemption” early access program under Section 4b of the German Drug Law.  Under this Hospital Exemption, NW Bio may provide DCVax-L to patients for the treatment of any glioma brain cancers (both Glioblastoma multiforme and lower grade gliomas), both newly diagnosed and recurrent, outside of the Company’s clinical trial and charge full price.  The patients may be from Germany or elsewhere.  This approval has a term of five years, and can be re-applied for and re-issued at the end of that period.

NW Bio also announced today that the German reimbursement authority (Institut Fur Das Entgeltsystem Im Krankenhaus, or InEK) has determined that DCVax-L treatments for glioma brain cancers are eligible to obtain reimbursement from the Sickness Funds (health insurers) of the German healthcare system.  Applications for such reimbursement eligibility may only be submitted to InEK by German hospitals, not by a company.  Six major hospital centers across Germany applied for such reimbursement eligibility for DCVax-L for glioma brain cancers.  The amount and terms for such reimbursement will now be negotiated by NW Bio, the hospitals and the Sickness Funds over the coming months, and will be applied to patients case by case.  In the meantime, patients may self-pay for DCVax-L.

The approval of the Hospital Exemption for DCVax-L is the culmination of nearly two years of regulatory processes and scrutiny, starting with a Scientific Advice process during 2012, and followed by an application for Hospital Exemption in December, 2012.  The evaluation of NW Bio’s application by the German regulatory authorities included comprehensive and detailed scrutiny of all aspects of the DCVax-L technology, all DCVax-L clinical data to date, all manufacturing processes, all product characteristics (including potency, composition, sterility and other aspects), all frozen storage of DCVax-L and frozen shelf life, and all distribution and handling of the DCVax-L products.

Although Section 4b of the German Drug law for Hospital Exemptions was implemented in July 2011, the approval for DCVax-L is the first such approval granted by the German regulatory authorities in multiple key ways.  Only two prior approvals have been given in the more than 2-1/2 years since the law was put in place, and those were for two German companies with tissue engineered products which had already been on the market commercially under prior laws and were grandfathered for regulatory purposes, and which did not have pharmacological (i.e., drug-like) effects in the patient’s body.

In contrast, DCVax-L is the first product of its kind to receive Hospital Exemption approval from the German regulators, in the following key ways:

• the first immunotherapy;
• the first product which exerts pharmacological (i.e., drug-like) effects in the patient’s body;
• the first product that has never previously been on the market commercially;
• the first product developed by a non-German company, not previously under the German regulators’ oversight;  and
• the first “somatic” cell therapy product (a somatic cell is any cell of the body other than a reproductive or embryonic cell).

Furthermore, the scope of the Hospital Exemption granted for DCVax-L is broader than the scope of NW Bio’s ongoing Phase III clinical trial (which must focus on a homogeneous set of patients in order to produce data that can be compared between treated and control patients).  The Hospital Exemption for DCVax-L applies to all glioma brain cancers, including both the most severe grade (Grade IV, Glioblastoma multiforme or GBM) and lower grade gliomas, while the clinical trial includes only GBM.  The Hospital Exemption also includes both newly diagnosed and recurrent gliomas, while the clinical trial includes only newly diagnosed.

Based upon data from the German Brain Tumor Association, there are approximately 7,000 new cases of gliomas (primary brain cancers) per year in Germany.  These would include approximately 3,000 cases of Glioblastoma multiforme (GBM), the most severe grade of glioma (Grade IV).

DCVax-L products that are to be covered by the Hospital Exemption in Germany must be manufactured in Germany, but can be administered to patients from anywhere.  As in the Company’s clinical trial, DCVax-L will be administered under the Hospital Exemption as an adjuvant treatment after surgical removal of the tumor and radiation/chemotherapy where applicable.  The Company will provide annual data reports to the German regulatory authority during the five-year term of the Hospital Exemption.

The Company expects to activate this program over the coming months.

“We are grateful to the PEI and InEK for these important decisions enabling DCVax-L to be made available to brain cancer patients now, and enabling reimbursement to be arranged with the Sickness Funds,” commented Linda Powers, CEO of NW Bio.  “We are also excited about the validation of our DCVax-L technology and our manufacturing, infrastructure and systems after such exhaustive scrutiny and evaluation by one of the toughest regulatory authorities.  Patients will now have a promising new treatment option, and the Company will have an invaluable opportunity to begin practicing now for commercial operations in the future.”

Prof. Dr. Frank Emmrich, the Director of Fraunhofer IZI, commented:  “This PEI decision, granting the Hospital Exemption approval to DCVax-L has achieved many ‘firsts’ and is a historic milestone.  Fraunhofer IZI is pleased to be part of the strong Team that achieved this approval, and we look forward to helping implement this much needed program.”

Dr. Zaklina Buljovcic, the Regulatory Expert on Innovative Therapies, of PharmaLex GmbH commented:  “We at PharmaLex are very happy and excited that a somatic cell therapy for glioma has received the first Hospital Exemption approval in Germany for a new product.  We also think that this approval is encouraging for universities and companies developing other cell therapies. Overall, it was great teamwork, and we appreciate the good cooperation with all parties involved, including the PEI.”

As a follow-up to this announcement, the Company will periodically provide further information about its Hospital Exemption program and reimbursement as the information becomes available.  Patients, physicians and others who would like to make inquiries about the program may do so using the following email addresses, or may contact the Contact Persons listed below.

• patients@nwbio.com
• physicians@nwbio.com
• investors@nwbio.com
• media@nwbio.com

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe.  The Company has a broad platform technology for DCVax dendritic cell-based vaccines.  The Company’s lead program is a 312-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM).  GBM is the most aggressive and lethal form of brain cancer, and is an “orphan disease.”  The Company is under way with a 60-patient Phase I/II trial with DCVax-Direct for all inoperable solid tumors cancers, with a primary efficacy endpoint of tumor regression.  The Company previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer.  The Company conducted a Phase I/II trial with DCVax for metastatic ovarian cancer together with the University of Pennsylvania.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as “expect,” “believe,” “intend,” “design,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the Company’s ability to raise additional capital, risks related to the Company’s ability to enroll patients in its clinical trials and complete the trials on a timely basis, uncertainties about the clinical trials process, uncertainties about the timely performance of third parties, risks related to whether the Company’s products will demonstrate safety and efficacy, risks related to the Company’s and Cognate’s abilities to carry out the intended manufacturing expansions contemplated in the Cognate Agreements, risks related to the Company’s ability to carry out the Hospital Exemption program and risks related to possible reimbursement and pricing.  Additional information on these and other factors, including Risk Factors, which could affect the Company’s results, is included in its Securities and Exchange Commission (“SEC”) filings.  Finally, there may be other factors not mentioned above or included in the Company’s SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

Logo – http://photos.prnewswire.com/prnh/20110329/SF73084LOGO

CONTACTS